Utama › Karsinoma Sel Skuamosa Kepala dan Leher › Kentucky › Louisville
Kajian klinikal Karsinoma Sel Skuamosa Kepala dan Leher di Louisville, KY
11 kajian untuk Karsinoma Sel Skuamosa Kepala dan Leher sedang mencari peserta di lokasi dalam dan sekitar Louisville (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Mengambil pesertaFasa 2/3
- Site#0111, Louisville
- Site#0115, Louisville
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Mengambil pesertaFasa 2
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Mengambil pesertaFasa 1
- Norton Cancer Institute, Louisville
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Mengambil pesertaFasa 2
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Mengambil pesertaFasa 2
- Norton Cancer Institute, Louisville
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Mengambil pesertaFasa 2
- Baptist Health Floyd, New Albany · 4 mi jauh
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
Mengambil pesertaFasa 3
- The James Graham Brown Cancer Center at University of Louisville, Louisville
- UofL Health Medical Center Northeast, Louisville
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Mengambil pesertaFasa 1/2
- Norton Cancer Institute, Louisville
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Mengambil pesertaFasa 1/2
- Norton Cancer Institue Downtown, Louisville
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Mengambil pesertaFasa 1
- Norton Cancer Institute /ID# 248903, Louisville
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Mengambil pesertaFasa 1/2
- Research Site 115, Louisville
Kajian Karsinoma Sel Skuamosa Kepala dan Leher di bandar lain
- Houston, TX47 kajian
- Los Angeles, CA42 kajian
- Boston, MA40 kajian
- New York City, NY39 kajian
- Nashville, TN39 kajian
- St. Louis, MO28 kajian
- Arlington, VA26 kajian
- Philadelphia, PA26 kajian
- Chicago, IL26 kajian
- Atlanta, GA24 kajian
- San Antonio, TX22 kajian
- New Haven, CT22 kajian
Kajian lain di Louisville
- Kanser Paru-paru Bukan Sel Kecil22 kajian
- Obesiti17 kajian
- Berat Badan Berlebihan15 kajian
- Kanser (semua jenis)14 kajian
- Kegagalan Jantung13 kajian
- Leukemia Mieloid Akut12 kajian
- Mieloma Pelbagai12 kajian
- Kanser Ovari12 kajian
- Kanser Payudara11 kajian
- Kanser Paru-paru11 kajian
- Melanoma10 kajian
- Kanser Prostat10 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.